Elan Reports Second Quarter 2009 Results

For the three months ended 2009, Elan has reported total revenues of $280.9m, compared to $245.6m for the same period, 2008. The operating loss of the company has also decreased to $16.5m, compared to $36.0m for same period, 2008. Elan has also reported a decrease in net loss to $68.2m, compared to $71.5m for the same period, 2008.

For the six month ended period, the company has posted a revenue of $526.0m, compared to $460.3m for previous year. The operating loss for the company decreased to $71.3m, compared to $81.6m for the previous year. The net loss for the company increased to $170.8m, compared to $157.0m for the previous year.

Kelly Martin, CEO of Elan, said, During the first six months of 2009, we grew revenues, added an additional approach to Alzheimer’s disease and successfully completed our strategic review with the announcement of a transformative transaction with Johnson & Johnson. Our focus will remain squarely on a disciplined and continuous investment in science and advancing our diversified clinical portfolio to patients.